Nevertheless, in the Middle Eastern region the only study of lung cancer-specific of EGFR mutation to date involves the levant population, the EGFR mutation was founded in 15.6% of NSCLC patients, which is lower than ours [17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.